PURPOSE OF REVIEW: Balloon catheter dilation (BCD) technology was introduced in 2005 as a device employed to dilate maxillary, sphenoid, and frontal sinus outflow tracts in patients with chronic sinus disease. With the evolution of the technology, BCD has been utilized in the office setting. The purpose of this review is to discuss the safety, tolerability, and technical success of this change of venue and to consider the possible significant cost savings in the current healthcare environment. RECENT FINDINGS: Recent studies have shown that BCD technology can be safely and successfully used in the office setting with high patient satisfaction and symptom improvement similar to that achieved in the operating room. SUMMARY: In select patients with chronic sinus disease, BCD can be safely and effectively utilized to open compromised outflow tracts from the peripheral sinuses including the maxillary, sphenoid, and frontal sinuses. This has the potential to reduce the overall costs related to the surgical treatment of medically refractory sinus disease.
PURPOSE OF REVIEW: Balloon catheter dilation (BCD) technology was introduced in 2005 as a device employed to dilate maxillary, sphenoid, and frontal sinus outflow tracts in patients with chronic sinus disease. With the evolution of the technology, BCD has been utilized in the office setting. The purpose of this review is to discuss the safety, tolerability, and technical success of this change of venue and to consider the possible significant cost savings in the current healthcare environment. RECENT FINDINGS: Recent studies have shown that BCD technology can be safely and successfully used in the office setting with high patient satisfaction and symptom improvement similar to that achieved in the operating room. SUMMARY: In select patients with chronic sinus disease, BCD can be safely and effectively utilized to open compromised outflow tracts from the peripheral sinuses including the maxillary, sphenoid, and frontal sinuses. This has the potential to reduce the overall costs related to the surgical treatment of medically refractory sinus disease.
Authors: Justin P McCormick; Melanie D Hicks; Jessica W Grayson; Bradford A Woodworth; Do-Yeon Cho Journal: Oral Maxillofac Surg Clin North Am Date: 2020-09-02 Impact factor: 2.802